Automating Endocrinology GLP-1 Prior Auth Workflows

The Challenge of High-Volume GLP-1 Prior Authorizations in Endocrinology

Endocrinology departments face substantial prior authorization volume for GLP-1 receptor agonists like Ozempic, Wegovy, Rybelsus, Victoza, Saxenda, Trulicity, Byetta, and Bydureon, as well as dual GIP/GLP-1 agonists such as Mounjaro and Zepbound. These medications, critical for Type 2 Diabetes (T2D) and obesity management, are subject to extensive payer scrutiny, leading to frequent delays and denials without robust automation.

Key Documentation and Criteria for GLP-1 Prior Auth

• **T2D Indications**: Payers often require A1c levels, documentation of prior medication trials (e.g., metformin), and specific contraindications. Adherence to step therapy protocols is critical, often guided by ADA Standards of Care and AACE Clinical Practice Guidelines.
• **Obesity Indications**: Coverage for medications like Wegovy and Zepbound typically mandates a BMI ≥30 (or ≥27 with comorbidity), evidence of prior weight-management interventions, and documentation of lifestyle modifications.
• **Payer Variability**: Coverage policies for obesity indications vary significantly by payer, requiring dynamic policy engine adaptation and precise clinical data capture from the EMR.

Common Denial Reasons for GLP-1 Therapies

Denials for GLP-1 prior authorizations frequently stem from specific gaps in documentation or restrictive payer policies. These include non-coverage for obesity indications, failure to meet step therapy requirements for T2D, and insufficient evidence of BMI criteria or prior weight-management efforts. Klivira's platform is engineered to proactively address these common denial triggers.

Klivira's Automated Workflow for Endocrinology GLP-1 PAs

Klivira integrates directly with your EMR to automate the entire GLP-1 prior authorization lifecycle. Our platform leverages SMART on FHIR capabilities to extract necessary clinical data, such as diagnosis codes, lab results (e.g., A1c), BMI, and medication history, streamlining submission through X12 278 transactions or payer portals.

How Klivira Optimizes GLP-1 Prior Authorizations

• **Indication-Aware Routing**: Automatically classifies and routes PAs based on T2D vs. obesity indications derived from EMR data.
• **Dynamic Payer Policy Engine**: Maintains up-to-date per-payer obesity benefit status, ensuring accurate submission and reducing denials.
• **Automated Step Therapy**: Validates and documents compliance with payer-mandated step therapy requirements, including prior metformin trials.
• **Brand-Specific Logic**: Applies distinct PA criteria for different GLP-1 products (e.g., Ozempic vs. Mounjaro) to ensure precise submissions.
• **Specialty Pharmacy Integration**: Facilitates post-approval routing to specialty pharmacies for seamless fulfillment of high-cost GLP-1 medications.
• **Patient Financial Counseling**: Surfaces manufacturer copay programs and alternative coverage paths when an obesity indication is denied by the payer.

Enhancing Revenue Cycle and Patient Access in Endocrinology

By automating the complex and high-volume endocrinology GLP-1 prior auth process, Klivira significantly reduces administrative burden, accelerates turnaround times, and minimizes denial rates. This allows your prior authorization coordinators to focus on complex cases, improving overall operational efficiency and ensuring patients receive timely access to necessary GLP-1 therapies.